Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
universal influenza dna vaccine
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
The universal influenza DNA vaccine (also known as UFlu) is a DNA-based prophylactic vaccine being developed by Orlance, Inc. for the prevention of seasonal and pandemic influenza. The vaccine utilizes Orlance's proprietary MACH-1 platform, a needle-free 'gene gun' technology that delivers powdered, DNA-coated microparticles directly into the epidermis, the skin's most immunologically active layer. By encoding conserved influenza antigens that remain consistent across multiple lineages, the vaccine aims to stimulate broad, long-lasting antibody and T-cell responses against a wide range of human, avian, and swine influenza strains. Currently in the IND-enabling stage, the program has received significant funding from the NIH SBIR program to support its advancement toward Phase 1 clinical trials.
- Other names
- Universal influenza vaccineMACH-1 universal influenza vaccineMACH1 universal influenza vaccineMACH 1 universal influenza vaccine
02
Targets
HA stem (Influenza A hemagglutinin stem region)
Beyond the preview
Go deeper on universal influenza dna vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on universal influenza dna vaccine.